Association between epidermal growth factor receptor mutation and chemotherapeutic efficacy in advanced non-small cell lung cancer patients / 中国医师杂志
Journal of Chinese Physician
; (12): 521-524, 2020.
Article
in Zh
| WPRIM
| ID: wpr-867275
Responsible library:
WPRO
ABSTRACT
Objective:The aim of the study was to investigate the association between epidermal growth factor receptor (EGFR) mutation and chemotherapeutic efficacy in advanced non-small cell lung cancer (NSCLC) patients.Methods:A total number of 490 patients with advanced non-small cell lung cancer were investigated in this retrospective study. Clinical outcomes were analyzed according to EGFR mutation status and mutation type based on Kaplan-Meier method and Cox regression model.Results:EGFR mutation was detected in 202 (41.2%) NSCLC patients. There was a trend that EGFR mutant patients had a higher response rate compared with wild type NSCLC patients, with non statistical significance (72.8% versus 66.0%, P=0.11). No difference was observed in progression free survival of first-line chemotherapy between EGFR negative and positive patients (6.00 versus 6.13 months, P=0.55). Patients harboring exon 19 deletion and exon 21 L858R point mutation derived similar progression free survival (PFS) (5.97 versus 6.23 months, P=0.79). Conclusions:EGFR mutation status and mutation type are not prognostic factors to first-line platinum-based chemotherapy in advanced NSCLC.
Full text:
1
Index:
WPRIM
Type of study:
Observational_studies
/
Prognostic_studies
Language:
Zh
Journal:
Journal of Chinese Physician
Year:
2020
Type:
Article